Publication: Últimos avances en el tratamiento neoadyuvante de cáncer de vejiga
| dc.contributor.author | Rioja, P | |
| dc.contributor.author | Valencia, G | |
| dc.contributor.author | Morante, Z | |
| dc.contributor.author | Paz, R | |
| dc.contributor.author | Vallejos, H | |
| dc.contributor.author | Fuentes-Rivera, H | |
| dc.contributor.author | Neciosup, S | |
| dc.date.accessioned | 2025-01-02T14:42:05Z | |
| dc.date.available | 2025-01-02T14:42:05Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Cisplatin-based neoadjuvant therapy has shown clear benefits in clinical stage II or IIIA muscle invasive bladder cancer (MIBC), achieving an impact in progression-free survival and overall survival. This updated review focuses on neoadjuvant therapy for MIBC, including the current recommendations from international and/or local practice guidelines, as well as studies of new therapeutic agents (immunotherapy, targeted therapy), on top of research on potential biomarkers that may predict response to immunotherapy. © 2022 Acta Medica Peruana. All rights reserved. | |
| dc.format | application/pdf | |
| dc.identifier.doi | 10.35663/amp.2022.391.2201 | |
| dc.identifier.journal | Acta Medica Peruana | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14703/271 | |
| dc.language.iso | spa | |
| dc.publisher | Colegio Medico del Peru | |
| dc.publisher.country | PE | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Biomarkers | |
| dc.subject | Immunotherapy | |
| dc.subject | Neoadjuvant Therapy | |
| dc.subject | Urinary Bladder Neoplasms | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.21 | |
| dc.title | Últimos avances en el tratamiento neoadyuvante de cáncer de vejiga | |
| dc.type | info:eu-repo/semantics/review | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dspace.entity.type | Publication |